![](https://cdn.statically.io/img/www.statnews.com/wp-content/uploads/2024/03/Adams-Biotech-Scorecard-Featured-Image-645x645.jpg)
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.
I’m back from my ASCO-Chicago detour. I missed you all!
This week, let’s argue over Geron’s future and consider Candel Therapeutics to illustrate why survival claims from non-randomized studies are too often red flags. I sound like a biotech nerd. I guess I am.
![STAT+](https://cdn.statically.io/img/www.statnews.com/wp-content/uploads/2022/02/stat_plus_hero_new-2048x502.png)
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect